Cel-Sci and Ergomed Sign Co-Development and Profit Sharing Agreement for Multikine in HIV/HPV Co-Infected Men and Women with Peri-Anal Warts
CEL-SCI Corporation announced that it has signed a co-development and profit sharing agreement with Ergomed Clinical Research Ltd. for CEL-SCI’s investigational immunotherapy drug Multikine (“Leucocyte Interleukin Inj.”) in HIV/HPV co-infected men and women with peri-anal warts. CEL-SCI has also recently entered a Cooperative Research and Development Agreement (CRADA) for this disease indication with the US Naval Medical Center, San Diego.
View full press release